



ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

EMVISION TECHNOLOGY TO BE PRESENTED AT PRESTIGIOUS INTERNATIONAL STROKE CONFERENCE

EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”), a medical device company focused on the development and commercialisation of medical imaging technology, is pleased to advise that a presentation on the EMVision technology titled “Electromagnetic (EM) Portable Imaging For Stroke”, has been accepted for the prestigious International Stroke Conference, New Orleans, February 2022.

Stroke neurologist and Australian Stroke Alliance clinical expert Dr Angela Dos Santos will be giving the presentation.

The International Stroke Conference is the world’s premier meeting dedicated to the science and treatment of cerebrovascular disease and brain health. The International Stroke Conference brings together thousands of healthcare professionals including neurologists, neurosurgeons, neuroradiologists and interventional radiologists, emergency medicine specialists, nurses and primary care physicians among others.

Australian Stroke Alliance co-chief investigators, Professors Stephen Davis and Geoffrey Donnan have welcomed the news. Prof Davis said: “The inclusion of this topic at the conference confirms the significant international interest in novel technologies with potential to provide prehospital stroke diagnosis. We are very pleased that neurologist and senior clinical fellow, a critical member of our project team, Dr Angela Dos Santos, will present an overview of the ground-breaking research collaboration between the Alliance and EMVision”.

Prof Donnan added: “The EM modality shows strong early promise for lightweight, portable neuroimaging and the early validation studies show that ischemic stroke, hemorrhagic stroke and stroke location can be distinguished within a given brain quadrant.”

Stroke neurologist, Dr Angela Dos Santos says: “I am pleased to be working closely with the EMVision team in a unique partnership, sharing my clinical knowledge, to develop a device that will change the lives of stroke patients, in particular those that live in rural and remote locations, without access to current imaging modalities needed to diagnose stroke subtypes. Presenting in New Orleans will allow the Australian Stroke Alliance to demonstrate the clear benefit of collaboration between clinician researchers and commercial developers, working together for medical advancement”.

EMVision CEO, Dr Ron Weinberger commented “We are pleased to feature in one of the world’s leading stroke conferences. The ISC 2022 provides a valuable opportunity to engage with key opinion leaders in the field of stroke and to demonstrate our commitment, alongside our collaborators at the Australian Stroke Alliance, to delivering innovative advances in stroke care.”

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys
Investor Relations
+61 400 400 800
andrew.keys@keysthomas.com

Sling & Stone
Media and Communications
emvision@slingstone.com
02 8073 5390

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventor Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging. EMVision's Chief Scientific Officer is Professor Stuart Crozier, who is a co-inventor and is globally renowned for creating technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$2 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Tropon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.